Use of Maribavir for Multidrug Resistant Cytomegaloviremia in a Pediatric Oncology Patient

James E. Fisher; Kevin Mulieri; Elizabeth Finch; Jessica E. Ericson

doi:10.1097/MPH.0000000000002841

Use of Maribavir for Multidrug Resistant Cytomegaloviremia in a Pediatric Oncology Patient

James E. Fisher, Kevin Mulieri, Elizabeth Finch, Jessica E. Ericson

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Resistant and refractory cytomegalovirus (CMV) viremia can limit the provision of chemotherapy due to myelosuppression and end-organ dysfunction. Few therapies are available for children with clinically significant CMV viremia. We successfully used maribavir for a 4-year-old patient with lymphoma to complete his chemotherapy course. Resistance to maribavir did result after many months of therapy.

Original language	English (US)
Pages (from-to)	E244-E247
Journal	Journal of pediatric hematology/oncology
Volume	46
Issue number	3
DOIs	https://doi.org/10.1097/MPH.0000000000002841
State	Published - Apr 1 2024

All Science Journal Classification (ASJC) codes

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1097/MPH.0000000000002841

Cite this

@article{c9ad31a6f436488c9627073eb7cf4c44,

title = "Use of Maribavir for Multidrug Resistant Cytomegaloviremia in a Pediatric Oncology Patient",

abstract = "Resistant and refractory cytomegalovirus (CMV) viremia can limit the provision of chemotherapy due to myelosuppression and end-organ dysfunction. Few therapies are available for children with clinically significant CMV viremia. We successfully used maribavir for a 4-year-old patient with lymphoma to complete his chemotherapy course. Resistance to maribavir did result after many months of therapy.",

author = "Fisher, {James E.} and Kevin Mulieri and Elizabeth Finch and Ericson, {Jessica E.}",

year = "2024",

month = apr,

day = "1",

doi = "10.1097/MPH.0000000000002841",

language = "English (US)",

volume = "46",

pages = "E244--E247",

journal = "Journal of pediatric hematology/oncology",

issn = "1077-4114",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Use of Maribavir for Multidrug Resistant Cytomegaloviremia in a Pediatric Oncology Patient

AU - Fisher, James E.

AU - Mulieri, Kevin

AU - Finch, Elizabeth

AU - Ericson, Jessica E.

PY - 2024/4/1

Y1 - 2024/4/1

N2 - Resistant and refractory cytomegalovirus (CMV) viremia can limit the provision of chemotherapy due to myelosuppression and end-organ dysfunction. Few therapies are available for children with clinically significant CMV viremia. We successfully used maribavir for a 4-year-old patient with lymphoma to complete his chemotherapy course. Resistance to maribavir did result after many months of therapy.

AB - Resistant and refractory cytomegalovirus (CMV) viremia can limit the provision of chemotherapy due to myelosuppression and end-organ dysfunction. Few therapies are available for children with clinically significant CMV viremia. We successfully used maribavir for a 4-year-old patient with lymphoma to complete his chemotherapy course. Resistance to maribavir did result after many months of therapy.

UR - http://www.scopus.com/inward/record.url?scp=85188839604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85188839604&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000002841

DO - 10.1097/MPH.0000000000002841

M3 - Article

C2 - 38447094

AN - SCOPUS:85188839604

SN - 1077-4114

VL - 46

SP - E244-E247

JO - Journal of pediatric hematology/oncology

JF - Journal of pediatric hematology/oncology

IS - 3

ER -

Use of Maribavir for Multidrug Resistant Cytomegaloviremia in a Pediatric Oncology Patient

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this